Jeremy E Graff

US Patent:

7601700, Oct 13, 2009

Filed:

Aug 1, 2008

Appl. No.:

12/184379

Inventors:

Kenneth Dobie - Del Mar CA, US
Eric G. Marcusson - San Francisco CA, US
Eric E. Swayze - Carlsbad CA, US
Balkrishen Bhat - Carlsbad CA, US
Jeremy Richard Graff - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN
ISIS Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C07H 21/02
C07H 21/04
A61K 31/70
C12N 5/00
C12Q 1/68

US Classification:

514 44, 435 6, 435375, 435377, 536 231, 536 241, 536 245

Abstract:

Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.

US Patent:

8410074, Apr 2, 2013

Filed:

Jul 13, 2012

Appl. No.:

13/548784

Inventors:

Kenneth W. Dobie - Del Mar CA, US
Eric G. Marcusson - San Francisco CA, US
Eric E. Swayze - Encinitas CA, US
Balkrishen Bhat - Carlsbad CA, US
Jeremy Richard Graff - Indianapolis IN, US

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C07H 21/02
C07H 21/04
A61K 31/70
C12Q 1/68

US Classification:

514 44A, 536 231, 536 241, 536 245, 435375, 435377

Abstract:

Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.

US Patent:

20070066549, Mar 22, 2007

Filed:

Sep 17, 2004

Appl. No.:

10/571339

Inventors:

Susan Freier - San Diego CA, US
Kenneth Dobie - Del Mar CA, US
Eric Marcusson - San Francisco CA, US
Eric Swayze - Carlsbad CA, US
Balkrishen Bhat - Carlsbad CA, US
Jeremy Graff - Indianapolis IN, US
Bruce Konicek - Indianapolis IN, US

International Classification:

A61K 48/00
A61K 38/16
C07H 21/02
A61K 31/704
A61K 31/522
A61K 31/403
A61K 31/4745
A61K 31/7072

US Classification:

514044000, 536023100, 514081000, 514008000, 514034000, 514171000, 514049000, 514283000, 514575000, 514410000, 514251000, 514263310, 424649000, 514651000

Abstract:

Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.

US Patent:

20100130589, May 27, 2010

Filed:

Aug 31, 2009

Appl. No.:

12/550479

Inventors:

Susan M. Freier - San Diego CA, US
Kenneth Dobie - Del Mar CA, US
Eric G. Marcusson - San Francisco CA, US
Eric E. Swayze - Carlsbad CA, US
Balkrishen Bhat - Carlsbad CA, US
Jeremy Richard Graff - Indianapolis IN, US
Bruce William Konicek - Indianapolis IN, US

International Classification:

A61K 31/7088
C07H 21/00
A61P 35/00

US Classification:

514 44 A, 536 245

Abstract:

Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.

US Patent:

20130178513, Jul 11, 2013

Filed:

Feb 28, 2013

Appl. No.:

13/780955

Inventors:

ISIS PHARMACEUTICALS, INC. - Carlsbad CA, US
Eric G. Marcusson - San Francisco CA, US
Eric E. Swayze - Encinitas CA, US
Jeremy Richard Graff - Indianapolis IN, US

Assignee:

ISIS PHARMACEUTICALS, INC. - Carlsbad CA

International Classification:

C07H 21/00

US Classification:

514 44 A, 536 245

Abstract:

Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.

US Patent:

20210283169, Sep 16, 2021

Filed:

Mar 29, 2021

Appl. No.:

17/215195

Inventors:

- New York NY, US
Keith Gorden - Woodberry MN, US
Anissa SH. Chan - Arden Hills MN, US
Steven Leonardo - Rosemount MN, US
Jeremy Graff - Indianapolis IN, US
Xiaohong Qiu - Edina MN, US
Takashi Kangas - Shoreview MN, US
Kathryn A. Fraser - St. Paul MN, US
Adria Bykowski Jonas - Eden Prairie MN, US
Nadine Ottoson - Lakeville MN, US
Ross Fulton - St. Paul MN, US

International Classification:

A61K 31/716
C12N 5/0783
A61K 39/395
C07K 16/28
C12N 5/0784
C12N 5/0786
C07K 16/30

Abstract:

This disclosure relates to the combination of soluble β-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

US Patent:

20200033362, Jan 30, 2020

Filed:

Feb 23, 2018

Appl. No.:

16/488911

Inventors:

- Eagan MN, US
Nadine OTTOSON - Lakeville MN, US
Ben HARRISON - Eagan MN, US
Jamie LOWE - Woodbury MN, US
Mark UHLIK - Indianapolis IN, US
Jeremy GRAFF - Indianapolis IN, US
Richard HUHN - St. Paul MN, US

Assignee:

BIOTHERA PHARMACEUTICALS, INC. - Eagan MN

International Classification:

G01N 33/68
A61K 31/716

Abstract:

This disclosure provides, in one aspect, dosing strategies for soluble β-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble β-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-β-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-β-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.

US Patent:

20190060350, Feb 28, 2019

Filed:

Oct 29, 2018

Appl. No.:

16/174157

Inventors:

- Eagan MN, US
Keith GORDEN - Woodbury MN, US
Anissa SH. CHAN - Arden Hills MN, US
Steven LEONARDO - Rosemount MN, US
Jeremy GRAFF - Indianapolis IN, US
Xiaohong QIU - Edina MN, US
Takashi KANGAS - Shoreview MN, US
Kathryn A. FRASER - St. Paul MN, US
Adria BYKOWSKI JONAS - Eden Prairie MN, US
Nadine OTTOSON - Lakeville MN, US
Ross FULTON - St. Paul MN, US

International Classification:

A61K 31/716
C07K 16/30
A61K 39/395
C12N 5/0783
C07K 16/28

Abstract:

This disclosure relates to the combination of soluble β-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

Address:

1229 W Henderson St, Chicago, IL 60657

VIN:

5J8TB18508A017790

Make:

ACURA

Model:

RDX

Year:

2008